ATE471334T1 - Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs - Google Patents

Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs

Info

Publication number
ATE471334T1
ATE471334T1 AT06710096T AT06710096T ATE471334T1 AT E471334 T1 ATE471334 T1 AT E471334T1 AT 06710096 T AT06710096 T AT 06710096T AT 06710096 T AT06710096 T AT 06710096T AT E471334 T1 ATE471334 T1 AT E471334T1
Authority
AT
Austria
Prior art keywords
cancer
treatment
nucleoside compounds
phosphoramidate derivatives
compounds
Prior art date
Application number
AT06710096T
Other languages
German (de)
English (en)
Inventor
Christopher Mcguigan
Kenneth Mills
Costantino Congiatu
Original Assignee
Cardiff Protides Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiff Protides Ltd filed Critical Cardiff Protides Ltd
Application granted granted Critical
Publication of ATE471334T1 publication Critical patent/ATE471334T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06710096T 2005-03-21 2006-03-16 Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs ATE471334T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0505781.5A GB0505781D0 (en) 2005-03-21 2005-03-21 Chemical compounds
PCT/GB2006/000932 WO2006100439A1 (en) 2005-03-21 2006-03-16 Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE471334T1 true ATE471334T1 (de) 2010-07-15

Family

ID=34531603

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06710096T ATE471334T1 (de) 2005-03-21 2006-03-16 Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs

Country Status (20)

Country Link
US (1) US8263575B2 (https=)
EP (1) EP1866324B1 (https=)
JP (2) JP5345381B2 (https=)
CN (2) CN101175763A (https=)
AT (1) ATE471334T1 (https=)
AU (1) AU2006226182C1 (https=)
BR (1) BRPI0609704B8 (https=)
CA (1) CA2602324C (https=)
CY (1) CY1111538T1 (https=)
DE (1) DE602006014949D1 (https=)
DK (1) DK1866324T3 (https=)
ES (1) ES2348741T3 (https=)
GB (1) GB0505781D0 (https=)
IL (1) IL186104A (https=)
MX (1) MX2007011666A (https=)
PL (1) PL1866324T3 (https=)
PT (1) PT1866324E (https=)
SI (1) SI1866324T1 (https=)
WO (1) WO2006100439A1 (https=)
ZA (1) ZA200709011B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
AU2012216500B2 (en) * 2006-11-24 2013-06-20 Katholieke Universiteit Leuven Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
US8759318B2 (en) 2009-01-09 2014-06-24 Inhibitex, Inc. Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
SG184324A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasset Llc Nucleoside phosphoramidates
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
EP2658857B1 (en) * 2010-12-29 2016-11-02 Inhibitex, Inc. Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
DK3031812T3 (en) 2011-03-01 2018-09-17 NuCana plc CHEMICAL COMPOUNDS
US9085599B2 (en) 2011-03-16 2015-07-21 Enanta Pharmaceuticals, Inc. 2′allene-substituted nucleoside derivatives
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
KR20170005492A (ko) * 2014-05-28 2017-01-13 아이데닉스 파마슈티칼스 엘엘씨 암의 치료를 위한 뉴클레오시드 유도체
MX2016015568A (es) * 2014-05-28 2017-07-04 Idenix Pharmaceuticals Llc Derivados de nucleosidos para el tratamiento del cancer.
LT3224268T (lt) * 2014-11-28 2019-09-25 NuCana plc Naujieji 2` ir (arba) 5` aminorūgšties esterio fosforamidato 3`-deoksi adenozino dariniai, kaip priešvėžiniai junginiai
CA3182565A1 (en) 2015-03-06 2016-09-15 Atea Pharmaceuticals, Inc. .beta.-d-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
CA3005444A1 (en) 2015-11-16 2017-05-26 Ichorion Therapeutics, Inc. Nucleic acid prodrugs
GB201522764D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609601D0 (en) * 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
WO2018048937A1 (en) 2016-09-07 2018-03-15 Atea Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
US11202792B2 (en) 2016-10-12 2021-12-21 Georgetown University CD99 inhibitors and their uses
GB201709471D0 (en) * 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
JP2020164521A (ja) * 2019-03-29 2020-10-08 国立大学法人 長崎大学 抗ウィルス薬
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (en) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Highly active compounds against covid-19
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880000094B1 (ko) * 1984-12-07 1988-02-23 보령제약 주식회사 뉴클레오시드 유도체의 제조방법
CA2004695C (en) 1988-12-12 1999-08-10 Rosanne Bonjouklian Phospholipid nucleosides
DE4418690A1 (de) 1994-05-28 1996-01-11 Boehringer Mannheim Gmbh Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
GB9505025D0 (en) * 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
EP0821692B1 (en) 1995-04-21 2006-01-11 University Of South Florida Immunopotentiating inosine monophosphate 5'-nucleotidase resistant derivatives and uses thereof
JP3761958B2 (ja) * 1996-03-12 2006-03-29 彰 松田 3′−カルバモイルアルキルヌクレオシド誘導体
IL137164A0 (en) * 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents
GB9821058D0 (en) * 1998-09-28 1998-11-18 Univ Cardiff Chemical compound
JP4768909B2 (ja) * 2000-09-29 2011-09-07 扶桑薬品工業株式会社 トポイソメラーゼ阻害剤
US20030073618A1 (en) * 2001-02-08 2003-04-17 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
DE10108851A1 (de) * 2001-02-23 2002-09-12 Resprotect Gmbh Verwendung von 5'-substituierten Nukleosiden und/oder deren Prodrugs zur resistenzfreien Therapie von Infektionskrankheiten
EP1478322A4 (en) 2001-06-22 2007-08-08 Pharmasset Ltd Beta 2'-OR 3'-HALONUCLEOSIDE
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0401088D0 (en) 2004-01-19 2004-02-18 Univ Cardiff Phosphoramidate derivatives
CA2571079A1 (en) * 2004-06-24 2006-02-02 Merck & Co., Inc. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
WO2007020193A2 (en) * 2005-08-15 2007-02-22 F. Hoffmann-La Roche Ag Antiviral phosphoramidates of 4 ' -substituted pronucleotides

Also Published As

Publication number Publication date
JP2013173786A (ja) 2013-09-05
JP5863702B2 (ja) 2016-02-17
SI1866324T1 (sl) 2010-10-29
IL186104A (en) 2013-06-27
EP1866324A1 (en) 2007-12-19
CY1111538T1 (el) 2015-08-05
DE602006014949D1 (de) 2010-07-29
MX2007011666A (es) 2007-11-14
CA2602324C (en) 2015-02-24
PT1866324E (pt) 2010-09-16
US8263575B2 (en) 2012-09-11
CN103936807A (zh) 2014-07-23
AU2006226182A1 (en) 2006-09-28
US20090215715A1 (en) 2009-08-27
CA2602324A1 (en) 2006-09-28
CN101175763A (zh) 2008-05-07
AU2006226182C1 (en) 2012-06-14
IL186104A0 (en) 2008-01-20
PL1866324T3 (pl) 2010-12-31
BRPI0609704A2 (pt) 2010-04-20
JP5345381B2 (ja) 2013-11-20
WO2006100439A1 (en) 2006-09-28
JP2008533191A (ja) 2008-08-21
ZA200709011B (en) 2009-01-28
BRPI0609704B1 (pt) 2020-12-01
DK1866324T3 (da) 2010-09-27
ES2348741T3 (es) 2010-12-13
GB0505781D0 (en) 2005-04-27
BRPI0609704B8 (pt) 2021-09-28
AU2006226182B2 (en) 2011-09-01
EP1866324B1 (en) 2010-06-16

Similar Documents

Publication Publication Date Title
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
DE602004015811D1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
TW200716141A (en) Compositions and methods for treatment for neoplasms
EA201692543A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
BRPI0513310A (pt) análogos de tetrapeptìdeo
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1126007T1 (el) Προαγωγεις αποπτωσης
TW200801008A (en) Protein kinase inhibitors
EP4023299C0 (en) 5-FLUORO-2'-DEOXYURIDINE PHOSPHORAMIDATE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
CY1112743T1 (el) Στερεοϊσομερως εμπλουτισμενες ενωσεις 3-αμινοκαρβονυλ δικυκλοεπτενο πυριμιδινοδιαμινης και οι χρησεις τους
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE502006005290D1 (de) Niedrigviskose uretdiongruppenhaltige polyadditionsverbindungen, verfahren zur herstellung und verwendung
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
MX2008001538A (es) Aril piridinas y metodos para su uso.
DE602007011324D1 (de) Verfahren zur herstellung von 2-substituierten 5-(1-alkylthio)alkylpyridinen
MX2010005324A (es) Composiciones y metodos para inhibir el avance del tumor.
EP1863520A4 (en) USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER
ATE397000T1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DK1606233T3 (da) Phospholipidestere af Clofarabin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1866324

Country of ref document: EP